Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the international expanded access program

Armando Santoro, Mary E. O'Brien, Rolf A. Stahel, Kristiaan Nackaerts, Paul Baas, Meinolf Karthaus, Wilfried Eberhardt, Luis Paz-Ares, Stein Sundstrom, Yushan Liu, Veronique Ripoche, Johannes Blatter, Carla M. Visseren-Grul, Christian Manegold

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Introduction:: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP. Methods:: Patients with histologically confirmed MPM, not amenable to curative surgery, received pemetrexed 500 mg/m in combination with either cisplatin 75 mg/m or carboplatin AUC 5, once every 21 days with standard premedication. Efficacy data were recorded at the end of study participation. Results:: A total of 1704 chemonaïve patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available. The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months). The most common grade 3/4 hematologic toxicity was neutropenia in 23.9% of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed plus carboplatin group. Conclusion:: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.

Original languageEnglish
Pages (from-to)756-763
Number of pages8
JournalJournal of Thoracic Oncology
Volume3
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Pemetrexed
Carboplatin
Cisplatin
Malignant Mesothelioma
Survival Rate

Keywords

  • Carboplatin
  • Cisplatin
  • Expanded access program
  • Malignant pleural mesothelioma
  • Pemetrexed

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma : Results of the international expanded access program. / Santoro, Armando; O'Brien, Mary E.; Stahel, Rolf A.; Nackaerts, Kristiaan; Baas, Paul; Karthaus, Meinolf; Eberhardt, Wilfried; Paz-Ares, Luis; Sundstrom, Stein; Liu, Yushan; Ripoche, Veronique; Blatter, Johannes; Visseren-Grul, Carla M.; Manegold, Christian.

In: Journal of Thoracic Oncology, Vol. 3, No. 7, 07.2008, p. 756-763.

Research output: Contribution to journalArticle

Santoro, A, O'Brien, ME, Stahel, RA, Nackaerts, K, Baas, P, Karthaus, M, Eberhardt, W, Paz-Ares, L, Sundstrom, S, Liu, Y, Ripoche, V, Blatter, J, Visseren-Grul, CM & Manegold, C 2008, 'Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the international expanded access program', Journal of Thoracic Oncology, vol. 3, no. 7, pp. 756-763. https://doi.org/10.1097/JTO.0b013e31817c73d6
Santoro, Armando ; O'Brien, Mary E. ; Stahel, Rolf A. ; Nackaerts, Kristiaan ; Baas, Paul ; Karthaus, Meinolf ; Eberhardt, Wilfried ; Paz-Ares, Luis ; Sundstrom, Stein ; Liu, Yushan ; Ripoche, Veronique ; Blatter, Johannes ; Visseren-Grul, Carla M. ; Manegold, Christian. / Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma : Results of the international expanded access program. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 7. pp. 756-763.
@article{3320b41fefad4965935653ae9b59a073,
title = "Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona{\"i}ve patients with malignant pleural mesothelioma: Results of the international expanded access program",
abstract = "Introduction:: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemona{\"i}ve patients receiving pemetrexed plus platinum under the EAP. Methods:: Patients with histologically confirmed MPM, not amenable to curative surgery, received pemetrexed 500 mg/m in combination with either cisplatin 75 mg/m or carboplatin AUC 5, once every 21 days with standard premedication. Efficacy data were recorded at the end of study participation. Results:: A total of 1704 chemona{\"i}ve patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available. The pemetrexed plus cisplatin group demonstrated a response rate of 26.3{\%} compared with 21.7{\%} for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1{\%} versus 64.0{\%}) and median time to progressive disease (7 months versus 6.9 months). The most common grade 3/4 hematologic toxicity was neutropenia in 23.9{\%} of the pemetrexed plus cisplatin group and 36.1{\%} of the pemetrexed plus carboplatin group. Conclusion:: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemona{\"i}ve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.",
keywords = "Carboplatin, Cisplatin, Expanded access program, Malignant pleural mesothelioma, Pemetrexed",
author = "Armando Santoro and O'Brien, {Mary E.} and Stahel, {Rolf A.} and Kristiaan Nackaerts and Paul Baas and Meinolf Karthaus and Wilfried Eberhardt and Luis Paz-Ares and Stein Sundstrom and Yushan Liu and Veronique Ripoche and Johannes Blatter and Visseren-Grul, {Carla M.} and Christian Manegold",
year = "2008",
month = "7",
doi = "10.1097/JTO.0b013e31817c73d6",
language = "English",
volume = "3",
pages = "756--763",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma

T2 - Results of the international expanded access program

AU - Santoro, Armando

AU - O'Brien, Mary E.

AU - Stahel, Rolf A.

AU - Nackaerts, Kristiaan

AU - Baas, Paul

AU - Karthaus, Meinolf

AU - Eberhardt, Wilfried

AU - Paz-Ares, Luis

AU - Sundstrom, Stein

AU - Liu, Yushan

AU - Ripoche, Veronique

AU - Blatter, Johannes

AU - Visseren-Grul, Carla M.

AU - Manegold, Christian

PY - 2008/7

Y1 - 2008/7

N2 - Introduction:: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP. Methods:: Patients with histologically confirmed MPM, not amenable to curative surgery, received pemetrexed 500 mg/m in combination with either cisplatin 75 mg/m or carboplatin AUC 5, once every 21 days with standard premedication. Efficacy data were recorded at the end of study participation. Results:: A total of 1704 chemonaïve patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available. The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months). The most common grade 3/4 hematologic toxicity was neutropenia in 23.9% of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed plus carboplatin group. Conclusion:: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.

AB - Introduction:: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP. Methods:: Patients with histologically confirmed MPM, not amenable to curative surgery, received pemetrexed 500 mg/m in combination with either cisplatin 75 mg/m or carboplatin AUC 5, once every 21 days with standard premedication. Efficacy data were recorded at the end of study participation. Results:: A total of 1704 chemonaïve patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available. The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months). The most common grade 3/4 hematologic toxicity was neutropenia in 23.9% of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed plus carboplatin group. Conclusion:: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.

KW - Carboplatin

KW - Cisplatin

KW - Expanded access program

KW - Malignant pleural mesothelioma

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=50349092664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349092664&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31817c73d6

DO - 10.1097/JTO.0b013e31817c73d6

M3 - Article

C2 - 18594322

AN - SCOPUS:50349092664

VL - 3

SP - 756

EP - 763

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -